What are the limitations of the evidence comparing vedolizumab versus ustekinumab for maintenance therapy in refractory pouchitis
What is known
- EARNEST is the only randomized double-blind placebo-controlled biologic trial in chronic pouchitis; vedolizumab beat placebo but was not compared to ustekinumab. 1,2 - Ustekinumab evidence is limited to single-center retrospective cohorts (e.g. 24 patients, 50% clinical response) and one prospective open-label multicenter study, no placebo or active comparator. 1,3 - Reviews state vedolizumab may be superior to anti-TNF for CARP induction but explicitly note there are no head-to-head RCTs among biologics. 4 - Earlier reviews classified both agents as case-series-level evidence, with EARNEST and the ustekinumab SOCRATES trial then ongoing. 5
What is unknown / caveats
- No direct or indirect comparative (head-to-head or network) analysis of the two agents - Ustekinumab data are largely retrospective/open-label without controls - Heterogeneous outcome definitions and CARP vs Crohn's-of-pouch inclusion criteria across studies - Endpoints skew to induction/short-term; durable maintenance data are sparse for both - The relative maintenance efficacy of vedolizumab versus ustekinumab in refractory pouchitis cannot be established from the retrieved evidence.
## References
1. Weber AT, Lichtenstein GR. Evidence-Based Approach to Chronic Antibiotic Refractory Pouchitis: A Review. Dis Colon Rectum. 2024;67:S99-s105. PMID: 38363696.
2. Uzzan M, Nachury M, Amiot A, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y, GETAID TOFA-POUCH study G. Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics. Dig Liver Dis. 2023;55:1158-1160. PMID: 37248123.
3. Mesonero F, Zabana Y, Fernández-Clotet A, Leo-Carnerero E, Caballol B, Núñez A, García MJ, Bertoletti F, Bastida G, Suris G, Casis B, Ferreiro-Iglesias R, Calafat M, Jiménez I, Miranda-Bautista J, Lamuela LJ, Fajardo I, Torrealba L, Nájera R, Sáiz-Chumillas RM, González-Partida I, Vicuña M, García-Morales N, Gutiérrez A, López-García A, Benítez JM, Rubín de Célix C, Tejido C, Brunet-Mas E, Hernandez-Camba A, Ferrer CS, Rodríguez-Lago I, Piqueras M, Castaño A, Ramos L, Sobrino A, Rodríguez-Grau MC, Elosua A, Montoro-Huguet MA, Baltar R, Huguet JM, Hermida B, Caballero-Mateos A, Sánchez-Guillén L, Bouhmidi A, Pajares R, Baston-Rey I, López-Sanromán A, Albillos A, Barreiro-de Acosta M. Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU. Ther Adv Gastroenterol. 2026;19:17562848261422373. PMID: 41732330.
4. Tome J, Raffals LE, Pardi DS. Management of Acute and Chronic Pouchitis. Dis Colon Rectum. 2022;65:S69-S76. PMID: 35905290.
5. Raine T, Verstockt B, Kopylov U, Karmiris K, Goldberg R, Atreya R, Burisch J, Burke J, Ellul P, Hedin C, Holubar SD, Katsanos K, Lobaton T, Schmidt C, Cullen G. ECCO Topical Review: Refractory Inflammatory Bowel Disease. J Crohns Colitis. 2021;15:1605-1620. PMID: 34160593.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
⚠ Required context not in this corpus (moderate). In EARNEST (PMID 36988594) every patient received concomitant ciprofloxacin during weeks 1-4, so the trial did NOT test vedolizumab induction WITHOUT a concomitant antibiotic.
_Why this matters:_ Citing EARNEST as evidence for vedolizumab alone misrepresents the trial design and can lead to withholding the antibiotic the responders actually received.
_Added by the landmark interlock. This corpus is surgical in scope and cannot admit the source paper (PMID 36988594). Not generated by the RAG._
---
_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._
Reviewer notes